Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

RIFM fragrance ingredient safety assessment, p-dimethoxybenzene, CAS Registry Number 150-78-7.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same author

RIFM fragrance ingredient safety assessment, isopropyl acetate, CAS Registry Number 108-21-4.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same author

RIFM fragrance ingredient safety assessment, isobutyl hexanoate, CAS Registry Number 105-79-3.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same author

RIFM fragrance ingredient safety assessment, ethyl acetoacetate, CAS Registry Number 141-97-9.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same author

RIFM fragrance ingredient safety assessment, 1-cyclohexene-1-acetic acid, CAS Registry Number 18294-87-6.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same author

RIFM fragrance ingredient safety assessment, 4-ethyloctanoic acid, CAS Registry Number 16493-80-4.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2019
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jun 14, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Enfermedad coronaria enfermedad coronaria.

D O'BRIEN

    Lancet (London, England)
    |March 19, 2010
    PubMed
    Resumen

    No abstract available in PubMed .

    Palabras clave:
    Vasos coronarios / enfermedades coronarias.

    Más Videos Relacionados

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
    13:07

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

    Published on: January 15, 2022

    Videos de Experimentos Relacionados

    Last Updated: Jun 14, 2026

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
    06:16

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

    Published on: August 9, 2024

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
    13:07

    Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

    Published on: January 15, 2022